# Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

> **NCT00306787** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1179 (actual)

## Conditions studied

- Genital Herpes

## Interventions

- **DRUG:** Famciclovir
- **DRUG:** Valacyclovir
- **DRUG:** Placebo matching famciclovir
- **DRUG:** Placebo matching valacyclovir

## Key facts

- **NCT ID:** NCT00306787
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 1179 (ACTUAL)
- **Last updated:** 2011-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306787, "Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00306787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*